Abstract
Pantethine (PaSS) was administered per orally at the dose of 600mg per day for 3 months to hemodialysis patients who were on a strict diet control and had taken no lipid lowering drugs. Serum total cholesterol (TC), triglycerides (TG), phospholipids (PL), and high density lipoproteincholesterol (HDL-C) levels were determined at 0, 1, 2, and 3 months after the drug treatment, respectively. As a result, the following findings were observed.
1) In hypercholesteremic subjects, TC levels were decreased with months while PaSS reversed the change in hypocholesteremics.
2) PaSS decreased TG levels in most of the patients, paticularly in hypertriglyceridemics.
3) PL levels gradually increased with months after PaSS administration regardless of the corresponding TC and TG levels.
4) HDL-C levels tended to be decreased at one month and significantly elevated at 3 months after treatment with PaSS in hypertriglycemics.
From our previous and present studies, we have confirmed that PaSS partially improves serum lipid abnormalities in hemodialysis patients even though long term administration of PaSS.
